A comprehensive view of Takeda Pharmaceutical Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Packaging Industry Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Takeda's HYQVIA approved by FDA as maintenance therapy for adult chronic inflammatory demyelinating polyneuropathy patient; the therapy can be infused up to once per month and can be administered by healthcare professionals or self-administered

Takeda selects Biologics by McKesson as specialty pharmacy provider for FDA-approved oral targeted therapy Fruzaqla for adults with metastatic colorectal cancer; the treatment is the first targeted therapy for the condition in over a decade

FDA approves Hutchmed's cancer drug fruquintinib for third-line treatment of metastatic colorectal cancer; Takeda acquired rights outside of China and will distribute it as Fruzaqla in the US, following US$400.0M upfront payment to Hutchmed

FDA approves several generic versions of Takeda's ADHD medication Vyvanse amid supply shortage due to manufacturing delays and increased demand; approved drugs made by Teva, Sun Pharmaceutical, Actavis, Mylan, and Hikma

Global Connected Packaging Summit, a free virtual event, to take place July 5-6; experts from Tetra Pak, Kellogg, Amazon, AB InBev, SIG, The Pack Hub, Seaman Paper, Plastic Bank, Takeda to discuss QR codes, NFC, AR, AI, ad technology, packaging, marketing

Ask us about our Packaging Industry market view

Trending Chart

Interactive chart with headline count